This would be consistent with observations from other research teams, which showed that significant increases in S100B levels in patients with end-stage renal disease (compared to a control group) are associated with complications of the disease, such as cognitive impairment [41]. This evidence concerns the gene S100B and stage 5 chronic kidney disease.